alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › imaging-abnormality

imaging-abnormality

4 studies tagged imaging-abnormality, dated 2025-01-24 to 2026-10-20. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Topography and risk factors of amyloid-related imaging abnormality: real-world data from 168 aducanumab-treated patients at a private clinic in South Korea 2026-10-20
  2. Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status 2026-08-13
  3. [Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab] 2025-02-01

Studies

4 studies carry this tag.

Date range

2025 to 2026

Top journals

  • Alzheimer's & dementia (Amsterdam, Netherlands) 1
  • Brain and nerve = Shinkei kenkyu no shinpo 1
  • Cureus 1
  • Journal of the Korean Society of Radiology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Topography and risk factors of amyloid-related imaging abnormality: real-world data from 168 aducanumab-treated patients at a private clinic in South Korea

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-10-20 Treatments

    ARIA-E risk during aducanumab therapy was influenced by genetic and clinical factors, supporting genotype-tailored titration in practice.

  2. Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Cureus 2026-08-13 Treatments

    In this real-world cohort of patients treated with lecanemab, ARIAs occurred in nearly one-third of patients.

  3. [Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab]

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain and nerve = Shinkei kenkyu no shinpo 2025-02-01 Treatments

    Lecanemab, the first monoclonal antibody drug targeting amyloid beta (Aβ), was approved for slowing the progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in the United States and Japan.

  4. Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the Korean Society of Radiology 2025-01-24 Treatments

    Lecanemab and donanemab have received full U.S. Food and Drug Administration (FDA) approval, and subsequently, lecanemab has been approved by the Korean FDA and it has recently entered commercial use in Korea.

All topic tags with their study counts